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Abstract: To combat emerging infectious diseases like Zika virus (ZIKV), synthetic messenger RNAs
(mRNAs) encoding viral antigens are very attractive as they allow a rapid, generic, and flexible
production of vaccines. In this work, we engineered a self-replicating mRNA (sr-mRNA) vaccine
encoding the pre-membrane and envelope (prM-E) glycoproteins of ZIKV. Intradermal electroporation
of as few as 1 µg of this mRNA-based ZIKV vaccine induced potent humoral and cellular immune
responses in BALB/c and especially IFNAR1-/- C57BL/6 mice, resulting in a complete protection
of the latter mice against ZIKV infection. In wild-type C57BL/6 mice, the vaccine resulted in very
low seroconversion rates and antibody titers. The potency of the vaccine was inversely related to
the dose of mRNA used in wild-type BALB/c or C57BL/6 mice, as robust type I interferon (IFN)
response was determined in a reporter mice model (IFN-β+/∆β-luc). We further investigated the
inability of the sr-prM-E-mRNA ZIKV vaccine to raise antibodies in wild-type C57BL/6 mice and
found indications that type I IFNs elicited by this naked sr-mRNA vaccine might directly impede
the induction of a robust humoral response. Therefore, we assume that the efficacy of sr-mRNA
vaccines after intradermal electroporation might be increased by strategies that temper their inherent
innate immunogenicity.
Keywords: self-replicating mRNA; Zika virus vaccine; type I interferon response; IFNAR1
knockout mice
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1. Introduction
Zika virus (ZIKV) is a mosquito-transmitted flavivirus that was isolated for the first time in 1947 in
the blood of a sentinel Rhesus monkey in the Zika forest of Uganda. Like other flaviviruses, ZIKV is an
enveloped, positive single-stranded RNA virus. Its full-length genome, which encodes three structural
proteins (C, prM, and E) and seven non-structural proteins (NS1, 2A, 2B, 3, 4A, 4B, and 5), is translated
as a large polyprotein that is cleaved by viral and host proteases [1]. The ZIKV envelope comprises
the membrane (M) and envelope (E) proteins. The M protein is derived from the pre-membrane
(prM) protein, which is cleaved during virus maturation into the M protein. The prM protein acts as a
chaperone and anchors the E protein in the lipid layer [2].
Until recently, ZIKV infections were associated with a mild self-limited illness, characterized
by fever, rash, fatigue, headache, conjunctivitis, and myalgia. The first signs that ZIKV was more
dangerous than originally thought were seen during the outbreak in French Polynesia (2013/2014),
where the ZIKV epidemic was linked with a surge in cases of Guillain–Barré syndrome [3–5]. Later on,
in 2016, the large ZIKV epidemic in South America pointed out that ZIKV was also responsible for fetal
malformations, such as microcephaly, cerebral calcifications, eye defects, and hearing loss [6]. In Rio de
Janeiro (Brazil), 42% of infants born from ZIKV-infected women had abnormal clinical or brain imaging
findings [7], while in French territories in the Americas, this percentage was much lower [8]. During
the outbreak in Brazil, more than 2800 babies with ZIKV-related fetal malformation were born [6,9].
Furthermore, there are indications that exposed but asymptomatic babies born from ZIKV-infected
mothers may have neurological abnormalities, such as vision and intellectual impairments, that are
not readily detected [10].
Although the ZIKV outbreak in South America faded at present, the transmission still progresses
at low and steady levels and recurrence is expected in the coming years [11,12]. Furthermore, high
mutation rates found in ZIKV can favor the genesis of new strains [13]. The severity of the disorders
caused by ZIKV and the real risk of new ZIKV outbreaks underpins the need of an effective and
safe vaccine. During the last years, several ZIKV vaccines based on inactivated or attenuated ZIKV,
virus-like particles, viral, or non-viral vectors (DNA and mRNA) have been tested in mice and
non-human primates [14–18]. Some of these ZIKV vaccines are currently evaluated in clinical trials [19].
The E protein, which is exposed at the surface of the viral particle, is the major target of neutralizing
antibodies. Hence, all subunits of ZIKV vaccines are based on this antigen. Moreover, it has been
shown that expression of the prM-E polyprotein of flaviviruses, like ZIKV, by (non-)viral vectors results
in the secretion of highly immunogenic virus-like particles (VLPs) that expose the E protein at their
surface [2,17]. Although vaccines based on viral vectors have a high potency, they have important
drawbacks such as a labor-intensive large-scale production process, the possible neutralization of
the viral vector by a pre-existing or induced adaptive immune response, and the risk of insertional
mutagenesis when integrating vectors are used [20]. Therefore, DNA and mRNA vaccines have been
studied as possible alternatives. However, DNA vaccines have shown only limited success in clinical
trials [21–24]. Moreover, there is also the potential risk that they may integrate in the genome [25].
Therefore, during the last decade, mRNA vaccines have emerged as safer and more potent alternatives
because, unlike DNA vaccines, they do not need to cross the nuclear membrane to be effective [26,27].
Indeed, mRNA delivery in the cytosol suffices to initiate translation into the desired protein. This
cytosolic delivery can be increased by non-viral carriers [28]. However, a drawback of non-viral carriers
is that they may cause in vivo toxicity and make the commercial production and registration of mRNA
therapeutics more complicated [29–32]. A humoral immune response after local administration (i.m. or
i.d.) of naked mRNA vaccines has only been obtained with self-replicating mRNAs (sr-mRNA), albeit
with a high variability and lower efficacy than lipid nanoparticle (LNP)-formulated sr-mRNA [33,34].
In this work, we designed and evaluated, for the first time, a naked sr-mRNA ZIKV vaccine
encoding the ZIKV prM-E. Intradermal electroporation of 1 µg of this unformulated ZIKV vaccine in
IFNAR1 knockout C57BL/6 mice (IFNAR1-/- mice) elicited highly reproducible antibody titers that
were comparable to previously reported titers after vaccination with formulated non-replicating and
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replicating mRNA ZIKV vaccines [14,35–37]. Moreover, all vaccinated IFNAR1-/- mice were protected
against ZIKV challenge. However, in wild-type (WT) C57BL6 mice, the vaccine elicited much lower
and highly variable antibody titers. Our data indicate that the elicited type I IFNs after intradermal
electroporation of the sr-prM-E-mRNA vaccine are responsible for this weak and highly variable
humoral immune response in these mice. This is in line with the study of Pepini et al. who also found
that the elicited type I IFNs by a formulated sr-mRNA vaccine against respiratory syncytial virus had a
negative impact on the antibody titers. They concluded that the type I IFNs suppressed the expression
of the antigen and that this resulted in lower antibody titers. However, we found indications that
the elicited type I IFNs might also have a direct negative effect on the induced immune cells after
sr-mRNA vaccination.
2. Materials and Methods
2.1. Mice
Female BALB/c mice (6–8 weeks old) were purchased from Janvier (France). Heterozygous IFN-β
reporter (IFN-β+/∆β-luc) mice [38,39] and IFNAR1 knockout (IFNAR1-/-) mice were kindly provided
by Prof. Johan Grooten (Department of Biomedical Molecular Biology, Ghent University), and Prof.
Roosmarijn E. Vandenbroucke (Department of Biomedical Molecular Biology, Ghent University),
respectively. The IFNAR1-/- mice were backcrossed for over 10 generations into a homogeneous
C57BL6/J background. All transgenic mice were bred in house and kept in individually ventilated cages
with free access to feed and water. Mice experiments were approved by the Ethics Committee of the
Faculty of Veterinary Medicine, Ghent University (No. EC2016/86 and No. EC2017/39). Experiments
with ZIKV were strictly conducted under Biosafety Level 2 (BSL-2) containment conditions.
2.2. Cells and Viruses
Baby hamster kidney cells (BHK-21) and Vero cells were purchased from American Type Culture
Collection (ATCC) and cultured at 37 ◦C and 5% CO2 in DMEM or EMEM, respectively, supplemented
with 10% inactivated fetal calf serum and 100 IU/ml penicillin/streptomycin. ZIKV strain MR-766 was
produced at the Institute of Tropical Medicine Antwerp (Belgium) and the infectious titers, expressed
as 50% tissue culture infective dose (TCID50) values, were determined in Vero cells using an endpoint
dilution assay as described by Reed and Muench [40].
2.3. Synthesis of Self-Replicating mRNA Encoding ZIKV PrM-E or Luciferase
The synthesis of the self-replicating mRNAs (sr-mRNAs) was performed by in vitro transcription
(IVT) as described [41,42]. Briefly, the sequence of the ZIKV prM-E fusion protein of the Brazilian
Rio-S1 ZIKV strain (GenBank No. KU926310.1, base 473 to 2488) or firefly luciferase (LUC) was
cloned into the pTK155 plasmid using Gateway Cloning (Invitrogen). The signal peptide of Japanese
encephalitis virus (JEV) was placed in front of the ZIKV prM-E sequence. The pTK155 plasmid was a
kind gift of dr. Tasuku Kitada and Prof. Ron Weiss (Massachusetts Institute of Technology, USA) and is
derived from Venezuelan Equine Encephalitis Virus (VEEV) strain TC-83 containing a point mutation
in the 5’UTR (A3G) and in the nsP2 leading to an amino acid substitution (Q739L). The engineered
plasmids were sequenced to ensure that they contained the correct inserts. To produce the VEEV-based
sr-prM-E-mRNA and sr-LUC-mRNA, the plasmids were transformed into competent Escherichia coli
(E. coli) bacteria and cultured in Luria broth (Invitrogen, Massachusetts, USA). After 16 h, the bacteria
were lysed and the plasmids were purified using the Plasmid Plus Midi kit (Qiagen, Germany).
Subsequently, the plasmids were linearized with I-SceI endonuclease (NEB, Massachusetts, USA)
and sr-mRNA were synthetized by IVT with the MEGAscript T7 Transcription kit (Life Technologies,
Massachusetts, USA). After IVT, the sr-mRNAs were purified and post-transcriptionally capped using
ScriptCap m7G Capping System and the 2’-O-Methyltransferase kit (Cellscript, Wisconsin, USA) to
obtain cap1. After capping, the sr-mRNAs were again purified using the RNeasy®Mini kit (Qiagen,
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Germany). A Poly(A) tailing was not required as a 40 nucleotide long poly(A) was encoded in the
linearized plasmid template. The quantity and quality of the sr-mRNAs were determined using a
Nanodrop spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA). The sr-mRNAs were
stored at −80 ◦C.
2.4. In Vitro Analysis of ZIKV E Protein Expression
BHK-21 cells were seeded in a 24-well plate (1 × 105 /well) and transfected at 70% confluency with
500 ng of sr-mRNA encoding ZIKV prM-E or LUC. Transfections were performed with lipofectamine
MessengerMax (Invitrogen) following the instructions of the manufacturer. Twenty-four hours after
transfection, culture supernatants were collected, and cells were subsequently lysed with RIPA buffer
for 1 h on ice. Then, 20 µl cell lysate samples were subsequently supplemented with an equal volume
of 2 × SDS-PAGE loading Buffer (4% SDS, 20% glycerol, 200mM DTT, 0.01% bromophenol blue, and
0.1 M Tris HCl, pH 6.8) and incubated for 10 min at 100 ºC before the loading of 15 µl samples on
SDS-PAGE gels. Following gel electrophoresis, the proteins were transferred onto PVDF membranes
by electroblotting (1 h at 100 V). Next, the membranes were blocked overnight at 4 ºC with 5% non-fat
milk in PBS with 0.2% Tween-80 (PBST). Membranes were then incubated with mouse anti-ZIKV-E
protein monoclonal antibody (BioFront Technologies, FL, USA) at 1:5000 for 2 h followed by three
washes with PBST. After that, the membranes were incubated with a 1:3000 dilution of HRP-conjugated
goat anti-mouse lgG (H+L) (GeneCopoeia) for 1 h at room temperature followed by three washes.
The membranes were analyzed using ECL western blotting detection kit (Thermo Scientific) and
pictured by the ChemiDoc XRS+ system (Bio-rad). For the dot blots, 3 µl of undiluted or 10-fold
and 100-fold-diluted supernatant was added directly to PVDF membranes. For the visualization
of the ZIKV E protein on these membranes, the same procedure was followed as described for the
Western blotting.
2.5. Preparation of Formalin-Inactivated ZIKV Vaccine
The formalin-inactivated ZIKV vaccine (FI-ZIKV) used in this study was prepared using the same
conditions as described previously [15]. In more details, a ZIKV isolate from the Dominican Republic
(GenBank KU853012, a kind gift from Luisa Barzon, University of Padova, Italy) was grown in Vero cells
and harvested after 4 days, followed by low speed centrifugation to remove cell debris and subsequent
ultracentrifugation through a 5% glycerol cushion. The pellet was subsequently resuspended in PBS.
To inactivate the purified ZIKV, the material was incubated with formalin (0.05%) at 22 ◦C for 7 days.
Subsequently, formalin was removed via dialysis. The inactivation of the virus was confirmed by
passaging the material on Vero cells and monitoring the development of a cytopathic effect.
2.6. Vaccination Experiments
Female IFNAR1-/- mice, having a C57BL/6 background, or WT C57BL/6 and BALB/c, were
vaccinated by two consecutive intradermal electroporations of the sr-prM-E-mRNA ZIKV vaccine
or the sr-LUC-mRNA (control). The dose of the sr-prM-E-mRNA ZIKV vaccine, sr-LUC-mRNA
control (1 or 10 µg in 50 µl), or FI-ZIKV (1 µg in 50 µl) was split over the left and right flanks of the
mice. Electroporation was performed immediately after each injection with a 2-needle array electrode
containing 4 needles per row of 4 mm (AgilePulse, BTX Harvard Apparatus, Massachusetts, USA) as
previously described [43]. The electroporation involved two short high-voltage pulses of 450 V with
duration of 0.05 ms and an interval of 300 ms followed by eight long low-voltage pulses of 100 V with
duration of 10 ms and an interval of 300 ms.
2.7. Innate Immune Response and Expression
The evoked innate immune response after intradermal electroporation of the sr-prM-E-mRNA
vaccine was monitored during 14 days in IFN-β reporter mice (IFN-β+/∆β-luc) using the same doses
and administration procedures as in the vaccination experiments. We also compared the expression
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profile of the sr-LUC-mRNA after intradermal electroporation in WT and IFNAR1-/- C57BL/6 mice.
Further, 1 or 10 µg of the sr-LUC-mRNA was intradermally electroporated and the luciferase expression
was followed for 28 days. To measure the in vivo luciferase expression, mice were subcutaneously
injected with 200 µl D-luciferin (15 mg/ml, Gold Biotechnology, USA) and 12 min later, the in vivo
bioluminescence signal was recorded using an IVIS Lumina II (PerkinElmer, USA).
2.8. Zika Virus-Specific Antibody Titers
ZIKV E protein-specific antibody titers were determined using the mouse ZIKV ELISA kit (Alpha
Diagnostic International, TX, USA). In more details, 96-well plates that were pre-coated with ZIKV
E protein were equilibrated for 5 min at room temperature with 300 µl of the provided wash buffer.
Subsequently, two-fold serial dilutions of the serum samples were made (starting from a 50-fold
dilution) and 100 µl of these dilutions was added per well along with the calibration standards. After
1 h of incubation at room temperature, the plates were washed four times with wash solution. Next,
100 µl of anti-mouse IgG HRP-conjugate working solution was added to the wells and incubated
at room temperature. After 30 min, the wells were washed five times and subsequently incubated
with 100 µl of 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate at room temperature. The enzymatic
conversion of TMB was stopped after 15 min by adding 100 µl of stop solution and the absorbance
was measured at 450 nm in a Biochrom EZ 400 microplate reader (Biochrom, England). The antibody
endpoint titers were defined as the highest reciprocal dilution with an absorbance that was at least two
times the background (obtained with serum of unvaccinated mice).
2.9. Zika Virus-Specific Cellular Immune Response
ZIKV-specific CD4+ and CD8+ T cells responses were determined by intracellular cytokine
staining with flow cytometry. In more detail, splenocytes were isolated four weeks after the boost and
stimulated in 96-well plates (1×106 cells/well) with 2 µg/ml of overlapping 15-amino-acid peptides
covering the ZIKV E protein (JPT, Berlin, Germany) in 1640 RPMI medium. After 1 h of stimulation at
37 ◦C 0.3 µl of eBioscience™ protein transport inhibitor cocktail (Brefeldin A 5.3 mM + Monensin 1 mM,
eBioscience) was added to 150 µl of stimulated splenocytes, and the samples were further incubated
for 5 h at 37 ◦C. Splenocytes were then harvested, washed with cold PBS, treated with mouse BD Fc
Block™ (BD Biosciences), and stained with anti-CD3-APC/CD4-PerCP/CD8-Alexa Fluor 488 antibodies
(clones 145-2C11, RM4-5 and 53-6.7, Biolegend) for 30 min at 4 ◦C according to manufacturer’s
instructions. Subsequently, the cells were fixed and permeabilized with the Fixation/Permeabilization
buffer (eBioscience) for 30 min at 4 ◦C before intracellular staining with anti-IFN-γ-PE antibody (clone
XMG1.2, Biolegend) for 30 min at room temperature. All the samples were finally washed and stored at
4 ◦C until analysis using a Cytoflex flow cytometer (Beckman Coulter). Single and live cells were gated
and 300,000 events were collected for each sample. Samples treated with Cell Stimulation Cocktail
(eBioscience) served as positive controls and unstimulated samples as negative controls.
2.10. Zika Virus Challenge
IFNAR-/- mice were intradermally electroporated with 1 µg of the sr-prM-E-mRNA ZIKV vaccine
or sr-LUC-mRNA using a prime-boost vaccination regimen with an interval of two weeks. Two weeks
after the boost, all the mice were infected in the footpad with 1000 TCID50 of ZIKV MR-766 in 25 µl
of PBS. One day before the ZIKV challenge, blood samples were taken to determine ZIKV specific
neutralization antibody titers. After ZIKV challenge, the body weight and disease symptoms were
monitored daily and a scoring system for weight loss and mobility impairment was used to determine
survival rates (supplementary Table S1). Blood samples were collected at day 1, 5, and 7 post-challenge
to assess viral RNA loads in plasma.
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2.11. ZIKV Virus Neutralization Tests
The virus neutralization test (VNT) was performed in Vero cells to measure the ZIKV-specific
neutralizing antibodies in the vaccinated mice prior to challenge. Serum samples were heat-inactivated
at 56 ◦C for 30 min and subsequently 3-fold serially diluted in assay medium consisting of EMEM
(Lonza) supplemented with 2 mM L-glutamine (Lonza), 100 U/ml Penicillin, 100 µg/ml Streptomycin
(Lonza), and 2% fetal bovine serum (Gibco). Next, ZIKV (strain MR766, African lineage) suspension
was added to each dilution to obtain 36 TCID50 (3 TCID100) per 100 µl of virus-serum mixtures.
The mixtures were subsequently incubated for 1h at 37 ◦C in 7% CO2. After that, 100 µl of each
virus-serum mixture was added to an equal volume of Vero cells containing 1.8 × 104 cells and each
serum dilution was tested in 8 replicates. The plates were cultured in a humid incubator at 37 ◦C
(7% CO2) and the cytopathic effect (CPE) in the cultures was evaluated microscopically after 1 week.
Neutralization titers were determined by counting the number of wells showing absence of CPE, and
NT50 and NT90 were calculated as the highest reciprocal dilution of the serum samples that resulted in,
respectively, 50% and 90% inhibition of viral infectivity using the Reed–Muench method [40].
2.12. Determination of Zika Virus RNA in Blood
One, five, and seven days after the ZIKV challenge, serum samples (40 µl) were collected from the
IFNAR1-/- mice and the RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen) according
to manufacturer’s instructions. The extracted RNA was then reverse-transcribed into cDNA and ZIKV
RNA was determined using the RealStar Zika Virus RT-PCR kit 1.0 (Altona diagnostics) following the
manufacturer’s protocol.
2.13. Statistical Analyses
All statistical analyses were performed using GraphPad Prism software (version 7.0, GraphPad
Software Inc., CA, USA) and data are represented as means ± SEM, unless otherwise mentioned.
One-way and two-way ANOVAs with Tukey’s multiple-comparison tests were used to analyze
statistically significant differences among different animal groups. Area under the curve (AUC) values
were calculated using the equation AUC =
∑
(ti+1 – ti)/2 × (Ci + Ci+1), where ti is the starting time
point, ti+1 is the finishing time point, Ci is the starting value, and Ci+1 is the finishing value for each
measurement over time. A p-value of <0.05 demonstrated statistically significant differences (*p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001).
3. Results
3.1. Construction of a Self-Replicating mRNA Expressing the ZIKV Pre-Membrane-Envelope Polyprotein
We designed a self-replicating (sr) mRNA encoding the codon-optimized full-length
pre-membrane-envelope (prM-E) protein of the Brazilian Rio-S1 ZIKV strain (GenBank No. KU926310.1).
The sequence of the Japanese encephalitis virus (JEV) signal peptide was cloned upstream of the prM-E
to improve its secretion and cleavage as demonstrated previously [44]. The JEV-prM-E sequence was
inserted following the non-structural proteins (nsPs) of Venezuelan equine encephalitis virus (VEEV,
strain TC-83) and flanked by the untranslated sequences of VEEV as depicted in Figure 1a. A control
sr-mRNA encoding luciferase (sr-LUC-mRNA) was also constructed (Figure 1a). Transfection of
BHK-21 cells with the sr-prM-E-mRNA ZIKV vaccine resulted in the production of a correctly processed
ZIKV E protein (54 kDa) in the cells and the secretion of the ZIKV E protein in the supernatant, as
verified by Western blot and dot blot, respectively (Figure 1b).
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Figure 1. Construction and characterization of a self-replicating (sr) mRNA vaccine against Zika virus
(ZIKV). (a) Depiction of the sr pre-membrane and envelope (prM-E) mRNA ZIKV vaccine with the
Japanese encephalitis virus (JEV) signal sequence in front of the prM-E, and the control sr-mRNA
encoding luciferase (sr-LUC-mRNA). The JEV-prM-E and luciferase sequences were codon-optimized.
The replication of the sr-mRNA is mediated by the four nonstructural proteins (nsPs) of Venezuelan
equine encephalitis virus (VEEV). The UTRs and the subgenomic promotor (SGP) are also derived
from VEEV. After transfection of the sr-prM-E-mRNA in baby hamster kidney (BHK)-21 cells, the
expression of the ZIKV E protein (~54 kDa) in the cells was detected by Western blot (b) and its secretion
in supernatant by dot blot (c) using monoclonal antibodies against ZIKV E protein and denaturing
conditions. BHK cells transfected with sr-LUC-mRNA served as negative controls.
3.2. Immunogenicity of the Sr-PrM-E-mRNA ZIKV Vaccine in BALB/c Mice
The immunogenicity of the sr-prM-E-mRNA ZIKV vaccine was first evaluated in BALB/c mice.
Animals (12 ice per group) were intradermally electroporated with 1 or 10 µg of the sr-prM-E-mRNA
ZIKV vaccine or with 1 µg of the sr-mRNA-LUC control. Aft r f ur we ks, all mice were boosted using
the same dose and procedure (Figure 2a). Mice that received 1 µg of the sr-prM-E-mRNA ZIKV vaccin
developed, four weeks after the prime, higher ZIKV E protein-specific IgG ntibodies than the mic
that received 10 µg of the vaccine (Figure 2b). Seroc nversion rates after the pri e were around 50% in
both groups (Figure 2c). The antibody respons s further increased after the boost in the 1 µg group
and became significantly hig r than the antib dy titers in the 10 µg group (Figure 2c). R markabl ,
the seroconversion rate dropped in the 10 µg group after the boost from 50% to 25%, while it increased
from 42% to 75% in the 1 µg group (Figure 2c). Mice immunized with the sr-LUC-mRNA control id
not develop detectable levels of anti-ZIKV E protein antibodies. In addition, the sr-prM-E-mRNA
ZIKV vaccine (1 µg group) also elicited ZIKV E protein-specific CD4+ and CD8+ T cell responses
as assessed by intracellular staining f IFN-γ in splenocytes, which were isolated four weeks after
the boost (Figure 2 ,e). These responses were signific tly higher than the background r sponses
observed in mice vaccinated with the control sr-LUC-mRNA. Interestingly, intradermal vaccination
of BALB/c mice with formalin-inactivated ZIKV (FI-ZIKV) vaccine i a prime-boost s tting elicited
high anti-ZIKV E protei -specific titers but failed to induce a ZIKV E protein-specific cellular immune
response (Figure 2).
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Figure 2. Immunogenicity of the sr-prM-E-mRNA and FI-ZIKV vaccines in BALB/c mice. (a) Mice were
intradermally electroporated on day 0 and 28 with either 1 or 10 µg of sr-prM-E-mRNA ZIKV vaccine,
1 µg of FI-ZIKV vaccine, or with 1 µg sr-LUC-mRNA. Antibody titers were determined four weeks after
the prime (b) or boost (c) by a ZIKV E protein-specific IgG ELISA ( = 12 in each group). The dashed
lines indicate t limit of detecti n of the assay. The lower panels depict ZIKV E protein-sp cific CD8+
(d) an CD4+ (e) T cell respons s in mice vaccinated wi 1 µg of sr-prM-E mRNA vaccine (n = 5 in
each group). Mi e vaccinated with either 1 µg sr-LUC-mRNA served as neg tive controls (n = 5). T cell
responses were determined four weeks after the boost by intracellular staining of IFN-γ in T cells
stimulated wi h a ZIKV E protein peptide pool (E p p +). Mice ec iving only alum adjuvant served
a co trols for the FI-ZIKV vaccin t m ce. These mice did not devel p ZIKV E protein-specific
antibodies or cellular immune responses, as observed for the sr-LUC-mRNA control mice (data not
shown). Data are represented as m an ± SEM and were analyzed by ANOVA followed by Tukey’s test.
3.3. Immunogenicity of the Sr-PrM-E-mRNA ZIKV Vaccine in IFNAR1-/- and WT C57BL/6 Mice
It was reported that BALB/c mice are resistant to infection with African and Asian ZIKV isolates [45].
Also, in our hands, BALB/c mice did not develop disease signs or detectable viremia upon subcutaneous
inoculation of up to 104 TCID50 of the ZIKV strain MR-766 (data not shown). Therefore, to further
evaluate the efficiency of our sr-prM-E-mRNA ZIKV vaccine, the ZIKV susceptible IFNAR1-/- C57BL/6
mice were used. WT and IFNAR1-/- C57BL/6 mice were immunized with 1 µg sr-prM-E-mRNA ZIKV
vaccine using the same vaccination protocol as for the BALB/c mice (Figure 3a). Remarkably, after
the prime and boost, IFNAR1-/- mice displayed significantly higher anti-ZIKV E protein IgG titers
and seroconversion rates than WT C57BL/6 mice (Figure 3b). After the booster vaccination, a tenfold
increase in antibody titers and a 100% seroconversion was obtained in IFNAR1-/- mice (Figure 3c).
In contrast, in WT C57BL/6 mice, antibody titers and seroconversion rates did not increase much after
the boost and remained extremely low in comparison to IFNAR1-/- and BALB/c mice immunized with
the same dose (Figures 2c and 3c). Moreover, increasing the dose of the sr-prM-E-mRNA ZIKV vaccine
in the WT C57BL/6 mice from 1 to 10 µg resulted in lower antibody titers and seroconversion rates
(Figure 3b,c). The ZIKV E-protein specific CD8+ T cell responses elicited by the sr-prM-E-mRNA ZIKV
vaccine were in IFNAR1-/- mice about three and two-fold higher than in BALB/c and WT C57BL/6 mice,
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respectively (Figures 3d and 2d). In contrast, the induced ZIKV E-protein specific CD4+ T cell responses
were very low in IFNAR1-/- and WT C57BL/6 mice and barely above the background responses of
control-vaccinated mice (Figure 3e).
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Figure 3. Immunogenicity of the sr-prM-E mRNA vaccine in IFNAR1-/- mice. (a) C57BL/6 wild-type (WT)
and IFNAR1-/- mice were intradermally electroporated on day 0 and 28 with 1 µg of sr-prM-E-mRNA
ZIKV v ccine. An additional group of WT mice was vaccinated in a similar way with a tenfold hi her
dose of the vaccine. Antibody titers in IFNAR1-/- and WT mice were determined four weeks after the
prime (b) or boost (c) by a ZIKV E-protein specific IgG ELISA (n = 6 or 8). The dashed lines indicate the
limit of detection of the assay. The lower panels show ZIKV E-protein specific CD8+ (d) and CD4+ (e)
T cell responses in IFNAR1-/- and WT mice receiving 1 µg sr-prM-E mRNA vaccine or sr-LUC-mRNA.
T cell responses were determined four weeks after the boost by intracellular staining of IFN-γ in T cells
stimulated with a ZIKV E protein peptide pool (E pep +) (n = 6 or 8). All data are represented as mean
± SEM and were analyzed by ANOVA followed by Tukey’s test.
3.4. The Interferon Response After Sr-PrM-E-mRNA ZIKV Vaccination Negatively Affects Antibody Titers
The introduction of a synthetic mRNA into mammalian cells may elicit an innate immune
response that results in the release of type I IFNs and inhibition of mR A ranslation [27]. Using IFN-β
luciferase reporter (IFN-β+/∆β-luc) mice, we confirmed that our sr-prM-E-mRNA ZIKV vaccine evokes
a strong and dose-dependent innate immune response directly after intradermal electroporation that
gradually decreases after 24 h (Figure 4a,b). Due to the impairment of the late-phase IFN response
in IFNAR1-/- mice, a higher translation of sr-mRNAs is expected, as they will elicit a much weaker
type I IFN response. We confirmed this hypothesis and found that IFNAR1-/- mice produced 10 times
more luciferase proteins than WT C57BL6 mice after intradermal electroporation of sr-LUC-mRNA
(Figure 4c,d). However, this difference in sr-mRNA-mediated protein expression might not be the only
possible explanation for the difference in anti-ZIKV immune responses between these two mice strains.
Indeed, 10 µg of sr-LUC-mRNA in WT C57/BL6 mice caused a similar luciferase expression as 1 µg
of sr-LUC-mRNA in IFNAR1-/- mice (Figure 4c,d), but the elicited antibody titers after vaccination
with 10 µg sr-prM-E-mRNA ZIKV vaccine in WT C57BL6 mice were much lower than the titers
elicited by 1 µg of the vaccine in IFNAR1-/- C57BL6 mice (Figure 3b,c). To evaluate the impact of
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mRNA replication in the induction of IFN- β signaling, we constructed a non-replicative truncated
sr-LUC-mRNA. The mRNA transfer in IFN-β+/∆β-luc mice confirmed, again, a dose-dependent IFN
response and highlighted that an early stage of IFN stimulation was independent of mRNA replication,
with peaking at 24 h and fading to background threshold after seven days (Figure S1).
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Figure 4. Interferon response after intradermal electroporation of the sr-prM-E mRNA ZIKV vaccine
and effect of IFNAR1 on the expression of sr-LUC-mRNA. (a) IFN-β luciferase reporter (IFN-β+/∆β-luc)
mice were intradermally electroporated with 1 or 10 µg of sr-prM-E-mRNA ZIKV vaccine and the type
I interferon response was monitored by measuring the bioluminescent signal at the injection spot for
14 days. The AUC of the curves in (a) are shown in (b) (n = 3). (c) C57BL/6 WT and IFNAR1-/- mice
were intradermally electroporated with 1 or 10 µg sr-LUC-mRNA and the luciferase expression was
determined by measuring the bioluminescent signal at the injection spot for 28 days. The results of the
statistical analysis of the data shown in (c) can be found Table S2. The AUC of the curves in (c) are
shown in (d) (n = 4). Data are represented as median with interquartile range and statistical analysis
was performed using ANOVA followed by Tukey’s test.
3.5. Protective Efficacy of the Sr-PrM-E-mRNA ZIKV Vaccine in IFNAR1-/- Mice
Finally, we determined whether the sr-prM-E-mRNA ZIKV vaccine was able to confer protection
against ZIKV infection. To that end, IFNAR1-/- mice (seven mice per group) were immunized with
1 µg of sr-prM-E-mRNA ZIKV vaccin or sr-LUC-mRNA control using prime-boost regimen with
a two-week interval, as the older IFNAR1-/- mice (over three onth old) were less susceptible to
ZIKV infection [46]. Using a virus neutralization test, we confirmed the presence of ZIKV-specific
neutralizing antibodies in the vaccinated mice two weeks after the boost and just before challenge
(Figure 5a,b). Subsequently, all mi e were challe ed with 1000 TCID50 of ZIKV MR-766 via t
footpad and disease symptoms, weight loss, viremia, morbidity, and mortality ere carefully monitored
(Figure 6). C ntrol mice started to lose weight on the third day following ZIKV challenge (Figure 6c).
On the sixth day post-infection, the control mice also started t show disease symp oms (Figu e 6b)
that further exacerbated until day 8 post ZIKV challenge. After that point, control mice that survived
the ZIKV infection sta ted to recov r. However, their weight stayed below that of vaccinated mice
uring the wh le experiment. The observed dis ase symp oms in control mice wer in accordance
with the high viral loads in their plasma (Figure 6d). Viremia peaked at day 5 and returned to baseline
at day 7 post-infection (Figure 6d). In contrast, none of the mice that were immunized with the
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sr-prM-E-mRNA ZIKV vaccine developed detectable viremia (<1000 copies/ml), disease symptoms, or
weight loss after ZIKV challenge (Figure 6b–d). Upon ZIKV challenge, none of the vaccinated mice
died, while four out of seven mice succumbed in the control group (Figure 6e)
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mRNA vaccine. M ce were intraderm lly electropo ated on d y 0 and 14 with 1 µg of sr-prM-E-mRNA
ZIKV vaccine or sr-LUC-mRNA and two we ks fter the b ost, ZIKV-specific neutralizing antibody
titers were determined by neutralization test (NT). The neutralizing an ibody titers are express d as
the reciprocal of the endpoint s rum dilution th t neutralized the challenge virus by (a) 50% (NT50)
or (b) 90% (NT90). The lower limit of NT quantification was 20 and is represented by the das ed lin
(n = 5 sr-prM-E-mR A gr up and n = 4 sr-LUC-mRNA group).
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Figure 6. Protective efficacy of the sr-prM-E mRNA vaccine in IFNAR1-/- mice. (a) Mice were
intradermally electroporated on day 0 and 14 with 1 µg of sr-prM-E-mRNA ZIKV vaccine or
sr-LUC-mRNA. Two weeks after the boost they were challenged by injecting 1000 TCID50 of ZIKV
(MR-766) in the footpad (n = 7); (b) The disease symptoms were daily recorded from day 5 to day 10
after ZIKV challenge and (c) the percentage of weight loss relative to the body mass just before ZIKV
infection was calculated; (d) the ZIKV RNA loads in plas a were determined by qRT-PCR. The dashed
line indicates the limit of detection of the assay; (e) survival rates were determined based on the scoring
system described in Table S1.
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4. Discussion
In this work, we designed a self-replicating mRNA encoding the prM-E protein of ZIKV. After
intracellular delivery of this sr-prM-E-mRNA vaccine, a correctly processed ZIKV E protein was
produced and secreted. The immunogenicity of this mRNA-based ZIKV vaccine was subsequently
evaluated in three different mouse models using intradermal electroporation. For the in vivo delivery
of mRNA vaccines, most preclinical and clinical studies make use of a non-viral carrier e.g., lipid
nanoparticles [26,27,47]. Nevertheless, the combination of our naked sr-prM-E-mRNA ZIKV vaccine
with local electroporation may hold some important advantages over carrier-mediated delivery, such as
a relatively simple commercial production process, a straightforward registration procedure, and less
concern about possible toxic effects of the carrier [29–32]. Moreover, in vivo electroporation systems
that are approved for clinical use in humans, like the Cliniporator®(IGEA, Carpi, Italy), are currently
used in many clinics to treat cancer patients with electrochemotherapy [48,49].
In ZIKV-susceptible IFNAR1-/- mice, which have a defective IFN type I signaling, intradermal
electroporation of only 1 µg sr-prME-mRNA vaccine elicited highly reproducible antibody titers
both in BALB/c mice and IFNAR-/- mice. The induced antibody titers in IFNAR-/- mice were
comparable to the titers previously obtained with formulated non-replicating or replicating mRNA
ZIKV vaccines [14,36,37]. Furthermore, the sr-prM-E-mRNA vaccine resulted in a 100% seroconversion
and provided complete protection against a ZIKV challenge. In BALB/c mice, the elicited mean
antibody titers were slightly lower and much more variable than the ones obtained in IFNAR1-/- mice.
In addition, 3 out of 12 BALB/c mice did not develop detectable antibodies titers after sr-prM-E-mRNA
vaccination. In C57BL/6 mice, the results were more disappointing, with a seroconversion of only 50%
and mean antibody titers below 100.
Using IFN-β reporter mice, we showed that intradermal electroporation of the sr-prM-E-mRNA
instantaneously elicits a strong and dose-dependent IFN-β response that peaks after 24 h and
subsequently gradually disappears. This rapid response indicates that not the cytosolic replication of
the sr-mRNA, but rather the intracellular influx of the sr-prM-E-mRNA is mainly responsible for the
elicited type I IFN response. To confirm this hypothesis, we made a replication-deficient sr-LUC-mRNA.
Intradermal electroporation of this replication-deficient sr-LUC-mRNA elicited a similar type I IFN
response in IFN-β reporter mice as a replication-competent sr-prM-E-mRNA (Supplementary Figure
S1).
Recently, Pepini et al. also reported that an LNP-formulated sr-mRNA vaccine elicited a
significantly higher expression and humoral response in IFNAR1-/- mice than in WT mice. These
authors reported that the lower expression in WT mice is a result of the type I IFNs elicited by the
sr-mRNA vaccine and they assumed that the lower antibody titers in WT mice are due to this lower
expression [50]. However, by comparing the expression and the antibody titers of our sr-prM-E-mRNA
ZIKV vaccine at different doses in WT and IFNAR1-/- mice we found clear indications that the elicited
type I IFNs also negatively impact the humoral response by other mechanisms than by reducing
the antigen expression. Intradermal electroporation of our sr-LUC-mRNA at 1 µg in IFNAR1-/-
mice or at 10 µg in WT mice resulted in a similar luciferase expression. However, intradermal
electroporation of 1 µg sr-prM-E-mRNA in IFNAR1-/- elicited a strong antibody response, while
intradermal electroporation of 10 µg sr-prM-E-mRNA in WT mice induced a very weak and variable
antibody response. These data indicate that the difference in antigen expression of the sr-prM-E-mRNA
in IFNAR1-/- and WT mice is not the only reason for the reduced antibody titers. We hypothesize that
the elicited type I IFNs not only lowered the expression of our naked sr-mRNA ZIKV vaccine, but
also negatively modulated the induced humoral immune response as previously reported in three
back-to-back publications in Science Immunology. In these papers, the poor induction of neutralizing
antibodies after a lymphocytic choriomeningitis virus (LCMV) infection was attributed to type I IFNs
that are induced after cellular entry of LCMV [51]. These papers unraveled several mechanisms by
which type I IFNs can interfere with the humoral immune response. Some of these mechanisms are
possibly also involved in the type I IFN-mediated blockage of the antibody response after intradermal
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vaccination with our naked sr-prM-E-mRNA vaccine. Moseman et al. found that the elicited type I
IFNs promote a CD8+ mediated killing of activated B cells that expose LCMV epitopes [52]. Sammicheli
et al. linked type I IFNs with lymph node recruitment of inflammatory monocytes, which prevent,
through their NO production, the development of long-lived antibody-secreting cells (ASCs) [53].
Finally, Fallet et al. concluded that the strong type I IFN response after LCMV infections results in
short-lived ASCs and that cytokines like IL-10 and TNF-β play a role in this phenomenon [54].
Messenger RNA-based ZIKV vaccines have shown excellent immunogenicity and protection
in four previous studies using BALB/c and C57BL/6 mice [14,35–37]. One can wonder why type I
IFNs did not negatively affect the immunogenicity of these mRNA ZIKV vaccines. Pardi et al. [14]
and Richner et al. [35] used LNP formulated modified non-replicating mRNAs, which are known
to have a very low inherent innate immune stimulating capacity [27]. A sr-prM-E-mRNA vaccine
similar to ours was recently evaluated by Erasmus et al. [36] and Chahal et al. [37]. In contrast to
our work, the sr-prM-E-mRNA vaccines in these studies were formulated into nanoparticles and
injected intramuscularly instead of intradermally. Indeed, we found that intradermal administration of
sr-mRNA induced a significantly higher type I IFN response than intramuscular route at the early stage
(Supplementary Figure S2). Additionally, in our sr-prM-E-mRNA vaccine, we used the JEV signal
peptide, while Erasmus et al. used a homotypic ZIKV signal peptide that resulted in significantly (up to
100-fold) higher neutralizing antibody titers. These differences may be responsible for the discrepancy
with our study.
Our hypothesis that the elicited type I IFNs suppressed the induction of anti-ZIKV antibodies is
further supported by the observation that increasing the dose of our sr-prM-E-mRNA vaccine from
1 to 10 µg resulted in a stronger IFN-β response (Figure 4a) and lower antibody titers (Figure 2b).
Additionally, the lower antibody titers and seroconversion rates in C57BL/6 mice (Figure 2b,c versus
Figure 3c) are also in agreement with the observation that C57BL/6 mice secrete significantly higher
levels of type I IFNs than BALB/c mice [55]. These data indicate that the strength of the elicited type I
IFN response is inversely proportional with the induced antibody titers, and that a certain threshold
of type I IFNs might be needed before they can suppress the humoral immune response. Therefore,
strategies that decrease the inherent innate immunity of sr-mRNA are expected to enhance the efficacy
of naked sr-mRNA vaccines after intradermal electroporation.
The formalin-inactivated ZIKV (FI-ZIKV) vaccine that we tested in our work evoked slightly
higher ZIKV specific antibody titers but failed to induce a cellular immune response. In contrast, the
sr-prM-E-mRNA ZIKV vaccine induced a robust CD8+ T cell response that largely exceeded previously
reported CD8+ responses with other ZIKV vaccines [14,15]. The CD8+ T cell response was higher in
IFNAR1-/- mice than in WT mice. This is in agreement with the work of De Beuckelaer et al. who also
found a better cellular immune response in IFNAR1-/- mice after immunization with a formulated
mRNA vaccine [39]. Although the humoral response is considered as the most important in the
protection against ZIKV infection, it has been shown that cellular immunity plays a non-negligible role
in controlling ZIKV infection [56,57]. Adoptive transfer of CD8+ T cells was shown to reduce viral
burden and mortality after ZIKV infection. Additionally, CD8+ T cells also provide protection against
ZIKV infection during pregnancy and can prevent antigen-induced antibody-dependent enhancement
of dengue disease in mice vaccinated against ZIKV [57,58].
The most devastating effects of a ZIKV infection are microcephaly and other distortions of the
growing fetuses. Consequently, it is meaningful to determine whether our ZIKV vaccine can protect
against these congenital malformations in pregnant mice. In a preliminary study, we observed that
unvaccinated mice that were challenged with ZIKV shortly after conception had reduced offspring
numbers (four pups from three mated females) compared to sr-prM-E-mRNA vaccinated females
(17 pups from 4 mated females). Furthermore, the offspring of unvaccinated mice were born death
and one of the four pups showed face malformation. These preliminary data might indicate that our
vaccine protects fetuses of pregnant mice against ZIKV. However, additional experiments are needed
to confirm and underpin these observations.
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5. Conclusions
In summary, intradermal electroporation of a naked self-replicating mRNA encoding the prM-E
of ZIKV elicited humoral and cellular responses in BALB/c and especially in IFNAR1-/- C57BL/6 mice,
resulting in complete protection of the latter mice against subsequent ZIKV challenge. In WT BALB/c
and C57BL/6 mice, the seroconversion rates and antibody titers were inversely related to the dose of
mRNA as well as the induced IFN-β response determined in a reporter mice model. The increased
seroconversion and antibody titers in IFNAR1-/- C57BL/6 indicate the negative impact of early IFN
response on sr-prM-E-mRNA vaccination. Nevertheless, a robust CD8+ T cell immune response was
observed in these mice. By comparing the expression and the antibody titers of our self-replicating
mRNA ZIKV vaccine at different doses in WT and IFNAR1-/- C57BL/6 mice, we conclude that the
elicited innate immune response after intradermal electroporation of our sr-mRNA ZIKV vaccine can
impede the humoral immune response by inhibiting the sr-mRNA translation, and possibly also via a
negative modulation of the induced humoral immune response.
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